Alteration of Jun proto-oncogene status by plasmid transfection affects growth of human ovarian cancer cells

International Journal of Cancer

Volumn 82, Issue 5, 1999, Pages 687-693

  De Gr̀eve, Jacques ^a   Neyns, Bart ^a   Teugels, Eric ^a   Bourgain, Claire ^b   Birrerand, Michael ^c  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METALLOTHIONEIN; PROTEIN C JUN; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL DEATH; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE C FOS; ONCOGENE C JUN; OVARY CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; COMPARATIVE STUDY; FEMALE; GENETICS; METABOLISM; ONCOGENE; OVARY TUMOR; PATHOLOGY;

ANIMALS; CELL DIVISION; FEMALE; GENES, JUN; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-JUN; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033609686     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990827)82:5<687::AID-IJC11>3.0.CO;2-F     Document Type: Article

References (21)

1. 1 phase in osteosarcoma. Int. J. Cancer, 74, 518-522 (1997).
2. FANG, X., JIN, X., XU, H.-J., LIU, L., PENG, H.-Q., HOGG, D., ROTH, J., YU, Y., XU, F., BAST, R. and MILLIS, G., Expression of p16 induces transcriptional down-regulation of the RB gene. Oncogene, 16, 1-8 (1998).
3. HERMAN, J., JEN, J., MERLO, A. and BAYLIN, S., Hypermethylation-associated inactivation indicates a tumor suppressor role for p151NK4B1. Cancer Res., 56, 722-727 (1996a).
4. HERMAN, J.G., GRAFF, R., MYOHANEN, S., NELKIN, B.D. and BAYLIN, S.B., Methylation-specific PCR: a novel PCR assay for methylation status of CpG island. Proc. nat. Acad. Sci. (Wash.), 96, 9821-9826 (1996b).
5. HUNTER, T. and PINES, J., Cyclin and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79, 573-582 (1994).
6. KARPEH, M.S., BRENNAN, M.F., CANCE, W.G., WOODRUFF, J.M., POLLACK, D., CASPER, E.S., DUDAS, M.E., LATRES, E., DROBNJAK, M. and CORDON-CARDO, C., Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Brit. J. Cancer, 72, 986-991 (1995).
7. LUKAS, J., PARRY, D., AAGAARD, L., MANN, D., BARTKOVA, J., STRAUSS, M., PETERS, G. and BARTEK, J., Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature (Lond.), 375, 503-506 (1995).
8. MAELANDSMO, G., BERNER, J.-M., FLORENES, V., FORUS, A., HOVIG, E., FODSTAD, O. and MYKLEBOST, O., Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas - relationship to amplification and mRNA levels of CDK4 and CCND1. Brit. J. Cancer, 72, 393-398 (1995).
9. MAELANDSMO, G., FLORENES, V, HOVIG, E., OYJORD, T., ENGEBRAATEN, O., HOLM, R., BORRESEN, A.-L. and FODSTAD, O., Involvement of the pRb/p16/ cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Brit. J. Cancer, 73, 909-916 (1996).
10. MARCHINI, S., CODEGONI, A., BONAZZI, C., CHIARI, S. and BROGGINI, M., Absence of deletions but frequent loss of expression of p16 ink4 in human ovarian tumours. Brit. J. Cancer, 76, 146-149 (1997).
11. MILLER, C., ASLO, A., CAMPBELL, M., KAWAMATA, N., LAMPKIN, B. and KOEFFLER, H., Alterations of p15, p16, and p18 in osteosarcoma. Cancer Genet. Cytogenet., 86, 136-142 (1996).
12. NOBORI, T., MIURA, K., WU, D., LOIS, A., TAKABAYASHI, K. and CARSON, D., Deletion of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancer. Nature (Lond.), 368, 753-756 (1994).
13. OTTERSON, G., KHLEIF, S., CHEN, W., COXON, A.B. and KAYE, F.J., CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16ink4 protein induction by 5-aza-2′ deoxycytidine. Oncogene, 11, 1211-1216 (1995).
14. SAMBROOK, J., FRITSCH, R.F. and MANIATIS, R., Molecular cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989).
15. SCHAPIRO, I., PARK, J., EDWARDS, C., MAO, L., MERLO, A., SIDRANSKY, D., EWEN, M. and ROLLINS, B., Multiple mechanisms of p16INK4 inactivation in nonsmall cell lung cancer cell lines. Cancer Res., 55, 6200-6209 (1995).
16. SERRANO, M., HANNON, G. and BEACH, D., A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366, 704-707 (1994).
17. SPILLARE, E., OKAMOTO, A., HAGIWARA, K., DEMETRICK, D., SERRANO, M., BEACH, D. and HARRIS, C., Suppression of growth in vitro and tumorigenicity in vivo of human carcinoma cell lines by transfected p16INK4. Mol. Carcinog., 16, 53-60 (1996).
18. TAKEUCHI, S., BARTRAM, C., SERIU, T., MILLER, C., TOBLER, A., JANSSEN, J., REITER, A., LUDWIG, W., ZIMMERMANN, M. and SCHWALLER, J., Analysis of a family of cyclin-dependent kinase inhibitors: p16/MTS2/INK4B, p16/MTS1/ INK4A and p18 genes in acute lymphoblastic leukemia of childhood. Blood, 86, 755-760 (1995).
19. 1 progression. Oncogene, 9, 2663-2674 (1994).
20. YEAGER, T., STADLER, W., BELAIR, C., PUTHENVEETTIL, J., OLOPADE, O. and REZNIKOFF, C., Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res., 55, 493-497 (1995).
21. ZETTERBERG, A., LARSSON, O. and WIMAN, K., What is the restriction point? Curr. Opin. Cell Biol., 7, 835-842 (1995).